TNF-alpha
Assets acting on this target.
- Class
- Anti-TNF inhibitor
- Pathway
- TNF-α signalling
Tumor necrosis factor-alpha (TNF-α) is a signaling protein, or cytokine, produced mainly by immune cells such as macrophages and T cells during inflammation. Under normal conditions it helps coordinate short-term immune defenses, recruiting other immune cells and inducing fever and tissue changes needed to fight infection or injury. In chronic inflammatory diseases, however, TNF-α is produced persistently and in excess, driving ongoing tissue damage. This is well documented in rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, where TNF-α perpetuates joint erosion, skin plaque formation, or intestinal ulceration. Blocking TNF-α, either by neutralizing the free cytokine or preventing it from engaging its cell-surface receptors, interrupts this self-sustaining inflammatory cycle and can substantially reduce disease activity across these conditions. This rationale has made TNF-α one of the most extensively targeted pathways in immunology, drugged by monoclonal antibodies, antibody fragments, fusion proteins, and increasingly small molecules. Some newer approaches pair TNF-α blockade with inhibition of a second inflammatory mediator, such as interleukin-17 or interleukin-23, reflecting the observation that several cytokine pathways often act together to sustain chronic inflammation, and that addressing more than one simultaneously may produce broader control than blocking TNF-α alone.
By indication
Related mechanisms
TNF-alpha drugs compared
23 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| adalimumabHumira | AbbVie | monoclonal antibody (fully human IgG1) | Approved | Approved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis |
| adalimumab-aacf (Idacio)Idacio | Fresenius SE & Co. KGaA | monoclonal antibody | Approved | Approved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis |
| adalimumab-aaty (Yuflyma)Yuflyma | Celltrion | monoclonal antibody | Approved | Approved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis |
| adalimumab-adaz (Hyrimoz)Hyrimoz | Cordavis, Sandoz Group AG | monoclonal antibody | Approved | Approved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis |
| adalimumab-adbm (Cyltezo)Cyltezo | Boehringer Ingelheim | monoclonal antibody | Approved | Approved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis |
| adalimumab-afzb (Abrilada)Abrilada | Pfizer | monoclonal antibody | Approved | Approved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis |
| adalimumab-aqvh (Yusimry)Yusimry | Hong Kong King-Friend Industrial Co., Ltd., Meitheal Pharmaceuticals | monoclonal antibody | Approved | Approved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis |
| adalimumab-atto (Amjevita)Amjevita | Amgen | monoclonal antibody | Approved | Approved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis |
| adalimumab-bwwd (Hadlima)Hadlima | Organon, Samsung Bioepis | monoclonal antibody | Approved | Approved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis |
| adalimumab-fkjp (Hulio)Hulio | Biocon | monoclonal antibody | Approved | Approved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis |
| adalimumab-ryvk (Simlandi)Simlandi | Alvotech, Teva Pharmaceutical Industries | monoclonal antibody | Approved | Approved in Crohn's Disease; Approved in Hidradenitis Suppurativa; Approved in Non-Infectious Uveitis; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis |
| certolizumab pegolCimzia | UCB | PEGylated anti-TNF Fab' fragment | Approved | Approved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis |
| etanerceptEnbrel | Amgen, Pfizer | fusion protein | Approved | Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis |
| golimumabSimponi | Johnson & Johnson | monoclonal antibody (fully human IgG1) | Approved | Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis; Phase 2 in Crohn's Disease |
| infliximabRemicade | Johnson & Johnson | monoclonal antibody (chimeric IgG1) | Approved | Approved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis |
| infliximab-abda (Renflexis)Renflexis | Organon, Samsung Bioepis | monoclonal antibody | Approved | Approved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis |
| infliximab-axxq (Avsola)Avsola | Amgen | monoclonal antibody | Approved | Approved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis |
| infliximab-dyyb (Inflectra)Inflectra | Celltrion, Pfizer | monoclonal antibody | Approved | Approved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis |
| infliximab-dyyb (Zymfentra)Zymfentra | Celltrion | monoclonal antibody | Approved | Approved in Crohn's Disease; Approved in Ulcerative Colitis |
| infliximab-qbtx (Ixifi)Ixifi | Pfizer | monoclonal antibody | Approved | Approved in Crohn's Disease; Approved in Psoriasis; Approved in Rheumatoid Arthritis; Approved in Ulcerative Colitis |
| JNJ-78934804 | Johnson & Johnson | Co-antibody combination (guselkumab + golimumab, SC) | Phase 3 | Phase 3 in Crohn's Disease; Phase 3 in Ulcerative Colitis |
| Hemay007 | Tianjin Hemay Pharmaceutical | small molecule | Phase 1 | Phase 1 in Crohn's Disease |
| SOR102 | Sorriso Pharmaceuticals | Biologic (oral dual TNFα/IL-23(p19) inhibitor) | Phase 1 | Phase 1 in Ulcerative Colitis |